JP2021500376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500376A5 JP2021500376A5 JP2020523261A JP2020523261A JP2021500376A5 JP 2021500376 A5 JP2021500376 A5 JP 2021500376A5 JP 2020523261 A JP2020523261 A JP 2020523261A JP 2020523261 A JP2020523261 A JP 2020523261A JP 2021500376 A5 JP2021500376 A5 JP 2021500376A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- binder
- seq
- cancer
- directed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100020750 Dipeptidyl peptidase 3 Human genes 0.000 claims 41
- 101000931862 Homo sapiens Dipeptidyl peptidase 3 Proteins 0.000 claims 41
- 239000011230 binding agent Substances 0.000 claims 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 20
- 230000001154 acute effect Effects 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 13
- 230000036542 oxidative stress Effects 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 208000020832 chronic kidney disease Diseases 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 206010040047 Sepsis Diseases 0.000 claims 5
- 206010040070 Septic Shock Diseases 0.000 claims 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 5
- 230000036303 septic shock Effects 0.000 claims 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000000523 end stage renal failure Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 208000028208 end stage renal disease Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000037797 influenza A Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024006108A JP2024041975A (ja) | 2017-10-25 | 2024-01-18 | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17198420.6 | 2017-10-25 | ||
| EP17198420 | 2017-10-25 | ||
| PCT/EP2018/079197 WO2019081595A2 (en) | 2017-10-25 | 2018-10-24 | DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006108A Division JP2024041975A (ja) | 2017-10-25 | 2024-01-18 | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500376A JP2021500376A (ja) | 2021-01-07 |
| JP2021500376A5 true JP2021500376A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JP7424972B2 JP7424972B2 (ja) | 2024-01-30 |
Family
ID=60186108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523261A Active JP7424972B2 (ja) | 2017-10-25 | 2018-10-24 | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
| JP2024006108A Pending JP2024041975A (ja) | 2017-10-25 | 2024-01-18 | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006108A Pending JP2024041975A (ja) | 2017-10-25 | 2024-01-18 | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11530276B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4527458A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7424972B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250111243A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118791621A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018356441B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020006563A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3080251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL274009B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004271A (cg-RX-API-DMAC7.html) |
| MY (1) | MY202502A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202002594PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019081595A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11530276B2 (en) * | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| CN113557031A (zh) * | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| EP4552649A3 (en) * | 2019-08-30 | 2025-06-25 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| AU2021228207A1 (en) * | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
| EP4121763A1 (en) * | 2020-03-16 | 2023-01-25 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| CN120359042A (zh) | 2022-12-15 | 2025-07-22 | 4Teen4制药有限公司 | 改善危重病患者肺功能的dpp3抑制剂 |
| CN115804836A (zh) * | 2022-12-27 | 2023-03-17 | 中国人民解放军海军特色医学中心 | 一种中枢小分子蛋白dpp3在制备降压药物中的应用 |
| CN120857945A (zh) | 2023-03-29 | 2025-10-28 | 4Teen4制药有限公司 | 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001016334A2 (en) | 1999-09-01 | 2001-03-08 | Incyte Genomics, Inc. | Human hydrolytic enzymes |
| WO2003020746A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (en) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| WO2007117444A2 (en) * | 2006-03-31 | 2007-10-18 | Yinghe Hu | Protein detection by aptamers |
| EP2302395B1 (en) | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| US8715928B2 (en) | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| EP2414542B1 (en) * | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| US9376477B2 (en) | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| WO2011073214A2 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| JP5902679B2 (ja) | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| CA2898596A1 (en) | 2013-01-28 | 2014-07-31 | Gabriel GOJON ROMANILLOS | Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| US20190145981A1 (en) * | 2016-04-21 | 2019-05-16 | Sphingotec Therapeutics Gmbh | Methods for determining dpp3 and therapeutic methods |
| US11530276B2 (en) * | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
-
2018
- 2018-10-24 US US16/758,881 patent/US11530276B2/en active Active
- 2018-10-24 EP EP25153152.1A patent/EP4527458A3/en active Pending
- 2018-10-24 CA CA3080251A patent/CA3080251A1/en active Pending
- 2018-10-24 CN CN202410933184.0A patent/CN118791621A/zh active Pending
- 2018-10-24 KR KR1020257023507A patent/KR20250111243A/ko active Pending
- 2018-10-24 MY MYPI2020002078A patent/MY202502A/en unknown
- 2018-10-24 BR BR112020006563-3A patent/BR112020006563A2/pt unknown
- 2018-10-24 WO PCT/EP2018/079197 patent/WO2019081595A2/en not_active Ceased
- 2018-10-24 CN CN201880069013.0A patent/CN111542548B/zh active Active
- 2018-10-24 EP EP18795970.5A patent/EP3700937A2/en active Pending
- 2018-10-24 JP JP2020523261A patent/JP7424972B2/ja active Active
- 2018-10-24 SG SG11202002594PA patent/SG11202002594PA/en unknown
- 2018-10-24 MX MX2020004271A patent/MX2020004271A/es unknown
- 2018-10-24 AU AU2018356441A patent/AU2018356441B2/en active Active
- 2018-10-24 IL IL274009A patent/IL274009B2/en unknown
- 2018-10-24 KR KR1020207014841A patent/KR102835427B1/ko active Active
-
2022
- 2022-11-10 US US17/984,611 patent/US20230295344A1/en active Pending
-
2024
- 2024-01-18 JP JP2024006108A patent/JP2024041975A/ja active Pending
-
2025
- 2025-03-06 AU AU2025201656A patent/AU2025201656A1/en active Pending